Current State of Art of the Therapy of WHO Grade III Gliomas in the Czech Republic

Czech version

Authors: O. Kalita ¹; F. Kramář ²; E. Neumann ³; T. Hrbáč ⁴; M. Bolcha ⁵; R. Brabec ⁶; R. Jančálek ⁷; D. Štěpánek ⁸; M. Bláha ⁹; P. Jurek ¹⁰; D. Malúšková ¹¹; J. Strenková ¹¹
Authors‘ workplace: Neurochirurgická klinika LF UP a FN Olomouc ¹; Neurochirurgická klinika 1. LF UK a ÚVN Praha ²; Neurochirurgická klinika LF MU a FN Brno ³; Neurochirurgická klinika LF OU a FN Ostrava ⁴; Neurochirurgická klinika UJEP a Krajská zdravotní a. s., Masarykova nemocnice v Ústí nad Labem, o. z. ⁵; Neurochirurgické oddělení, Krajská nemocnice Liberec, a. s. ⁶; Neurochirurgická klinika LF MU a FN U sv. Anny v Brně ⁷; Neurochirurgické oddělení, FN Plzeň ⁸; Neurochirurgická klinika 2. LF UK a FN v Motole, Praha ⁹; Neurochirurgické oddělení, Krajská nemocnice T. Bati, a. s., Zlín ¹⁰; Institut biostatistiky a analýz, LF MU, Brno ¹¹
Published in: Cesk Slov Neurol N 2015; 78/111(3): 306-316
Category: Original Paper

Overview

The aim of our paper is to evaluate treatment results for WHO grade III gliomas in the Czech Republic. We performed an assessment of a sample of patients from the glioma tumor DoIT registry. Data on 226 patients diagnosed with WHO grade III gliomas between 1 January 2007 and 31 December 2012 in ten centers were available for statistical analysis. We failed to prove an effect of gender on overall survival. However, a positive effect of patient age, oligodendroglial tumor component (median survival – 45.3 months), extent of resection (median survival – 25.4 months), chemoradiotherapy vs. radiotherapy alone (median survival – 33.1 vs. 11.6 months) was shown as well as a synergic effect of total tumor resection plus chemoradiotherapy on overall survival (median survival – 36 months). Temozolomide was the first‑ choice chemotherapy regimen in all centers; PCV chemotherapy was initially administered in one case of oligo‑ glioma only. The analysis also implies that implementation of cytogenetic investigation of prognostic markers (MGMT, 1p/ 19q, IDH, ATRX) into standard laboratory procedures is required if individualized therapy of WHO grade III glioma is to take place. WHO grade III gliomas are a very heterogeneous group of tumors with different prognosis and treatment response. Virtually all comprehensive cancer centers have appointed neuro‑oncologic teams including neurologists and neurosurgeons who thus participate in establishing the general management strategy for WHO grade III gliomas.

Key words:
anaplastic gliomas – general management strategy – radical resection – chemoradiotherapy

The authors declare they have no potential conflicts of interest concerning drugs, products, or services used in the study.

The Editorial Board declares that the manuscript met the ICMJE “uniform requirements” for biomedical papers.

Sources

1. Wick W. Anaplastic gliomas: an emerging entity. Eur J Cancer 2011; 47 (Suppl 3): S357– S358. doi: 10.1016/ S0959‑ 8049(11)70202‑ 7.

2. Kros JM, Gorlia T, Kouwenhoven MC, Zheng PP, Collins VP, Figarella‑ Branger D et al. Panel review of anaplastic oligodendroglioma from European Organization For Research and Treatment of Cancer Trial 26951: assessment of consensus in diagnosis, influence of 1p/ 19q loss, and correlations with outcome. J Neuropathol Exp Neurol 2007; 66(6): 545– 551.

3. Stummer W, Pichlmeier U, Meinel T, Wiestler OD, Zanella F, Reulen HJ. Fluorescence‑ guided surgery with 5- aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol 2006; 7(5): 392– 401.

4. Stummer W, Reulen HJ, Meinel T, Pichlmeier U, Schumacher W, Tonn JC et al. ALA‑ Glioma Study Group. Extent of resection and survival in glioblastoma multiforme: identification of and adjustment for bias. Neurosurgery 2008; 62(3): 564– 576. doi: 10.1227/ 01.neu.0000317304.31579.17.

5. Sanai N, Polley MY, McDermott MW, Parsa AT, Berger MS. An extent of resection threshold for newly diagnosed glioblastomas. J Neurosurg 2011; 115(1): 3– 8. doi: 10.3171/ 2011.2.JNS10998.

6. Hardesty DA, Sanai N. The value of glioma extent of resection in the modern neurosurgical era. Front Neurol 2012; 18(3): 140. doi: 10.3389/ fneur.2012.00140.

7. Marko NF, Weil RJ, Schroeder JL, Lang FF, Suki D, Sawaya RE.Extent of resection of glioblastoma revisited: personalized survival modeling facilitates more accurate survival prediction and supports a maximum‑ safe‑ resection approach to surgery. J Clin Oncol 2014; 32(8): 774– 782.

8. Sanai N. Emerging operative strategies in neurosurgical oncology. Curr Opin Neurol 2012; 25(6): 756– 766. doi: 10.1097/ WCO.0b013e32835a2574.

9. Wick W, Hartmann C, Engel C, Stoffels M, Felsberg J, Stockhammer F et al. NOA‑ 04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide. J Clin Oncol 2009; 27(35): 5874−5882. doi: 10.1200/ JCO.2009.23.6497.

10. Shirai K, Suzuki Y, Okamoto M, Wakatsuki M, Noda SE, Takahashi T et al. Influence of histological subtype on survival after combined therapy of surgery and radiation in WHO grade 3 glioma. J Radiat Res 2010; 51(5): 589– 594.

11. Lassman AB, Iwamoto FM, Cloughesy TF, Aldape KD, Rivera AL, Eichler AF et al. International retrospective study of over 1,000 adults with anaplastic oligodendroglial tumors. Neuro Oncol 2011; 13(6): 649– 659. doi: 10.1093/ neuonc/ nor040.

12. Cairncross JG, Ueki K, Zlatescu MC, Lisle DK, Finkelstein DM, Hammond RR et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 1998; 90(19): 1473−1479.

13. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352(10): 987−996.

14. Marucci G. The effect of WHO reclassification of necrotic anaplastic oligoastrocytomas on incidence and survival in glioblastoma. J Neurooncol 2011; 104(2): 621– 622. doi: 10.1007/ s11060‑ 010‑ 0523‑ z.

15. van den Bent MJ, Carpentier AF, Brandes AA, Sanson M, Taphoorn MJ, Bernsen HJ et al. Adjuvant procarbazine, lomustine, and vincristine improves progression‑free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organization for Research and Treatment of Cancer phase III trial. J Clin Oncol 2006; 24 (18): 2715−2722.

16. Cairncross G, Berkey B, Shaw E, Jenkins R, Scheithauer B, Brachman D et al. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol 2006; 24(18): 2707−2714.

17. Cairncross G, Wang M, Shaw E, Jenkins R, Brachman D,Buckner J et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long‑term results of RTOG 9402. J Clin Oncol 2013; 31(3): 337– 343. doi: 10.1200/ JCO.2012.43.2674.

18. van den Bent MJ, Brandes AA, Taphoorn MJ, Kros JM,Kouwenhoven MC, Delattre JY et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long‑term follow‑up of EORTC brain tumor group study 26951. J Clin Oncol 2013; 31(3): 344– 350. doi: 10.1200/ JCO.2012.43.2229.

19. Brada M, Stenning S, Gabe R, Thompson LC, Levy D,Rampling R et al. Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high‑grade glioma. J Clin Oncol 2010; 28(30): 4601−4608. doi: 10.1200/ JCO.2009.27.1932.

20. Iwadate Y, Matsutani T, Shinozaki N, Saeki N. Anaplastic oligodendroglial tumors harboring 1p/ 19q deletion can be successfully treated without radiotherapy. Anticancer Res 2011; 31(12): 4475– 4479.

21. Taphoorn MJ, van den Bent MJ, Mauer ME, Coens C,Delattre JY, Brandes AA et al. Health‑related quality of life in patients treated for anaplastic oligodendroglioma with adjuvant chemotherapy: results of a European Organisation for Research and Treatment of Cancer randomized clinical trial. European Organisation for Research and Treatment of Cancer. J Clin Oncol 2007; 25(36): 5723– 5730.

22. Gorlia T, Delattre JY, Brandes AA, Kros JM, Taphoorn MJ,Kouwenhoven MC et al. New clinical, pathological and molecular prognostic models and calculators in patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951. Eur J Cancer 2013; 49(16): 3477– 3485. doi: 10.1016/ j.ejca.2013.06.039.

23. van den Bent MJ, Dubbink HJ, Sanson M, van der Lee‑ Haarloo CR, Hegi M, Jeuken JW et al. MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951. J Clin Oncol 2009; 27(35): 5881– 5886. doi: 10.1200/ JCO.2009.24.1034.

24. van den Bent MJ, Dubbink HJ, Marie Y, Brandes AA, Taphoorn MJ, Wesseling P et al. IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Clin Cancer Res 2010; 16(5): 1597– 1604. doi: 10.1158/ 1078‑ 0432.CCR‑ 09‑ 2902.

25. Kramař F, Zemanová Z, Michalová K, Babická L, Ransdorfová S, Kozler P et al. Patogeneze mozkových gliomů, II. čast: Patogeneze oligodendrogliomů a gliomů v ramci dědičných onemocněni. Cesk Slov Neurol N 2006; 69/ 102(6): 419– 425.

26. Paleologos NA, Merrell RT. Anaplastic glioma. Curr Treat Options Neurol 2012; 14(4): 381– 390. doi: 10.1007/ s11940‑ 012‑ 0177‑ 6.

27. Giannini C, Burger PC, Berkey BA, Cairncross JG, Jenkins RB, Mehta M et al. Anaplastic oligodendroglial tumors: refining the correlation among histopathology, 1p/ 19q deletion and clinical outcome in Intergroup Radiation Therapy Oncology Group Trial 9402. Brain Pathol 2008; 18(3): 360– 369. doi: 10.1111/ j.1750‑ 3639.2008.00129.x.

28. Hartmann C, Meyer J, Balss J, Capper D, Mueller W,Christians A et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol 2009; 118(4): 469– 474. doi: 10.1007/ s00401‑ 009‑ 0561‑ 9.

29. Zhao S, Lin Y, Xu W, Jiang W, Zha Z, Wang P et al. Glioma‑ derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF‑ 1alpha. Science 2009; 324(5924): 261– 265. doi: 10.1126/ science.1170944.

30. Shibahara I, Sonoda Y, Kanamori M, Saito R, Kumabe T, Tominaga T. New insights into glioma classification based on isocitrate dehydrogenase 1 and 2 gene status. Brain Tumor Pathol 2011; 28(3): 203– 208. doi: 10.1007/ s10014‑ 011‑ 0050‑ 4.

31. Jiao Y, Killela PJ, Reitman ZJ, Rasheed AB, Heaphy CM, de Wilde RF et al. Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas. Oncotarget 2012; 3(7): 709– 722.

32. Wiestler B, Capper D, Holland‑ Letz T, Korshunov A, von Deimling A, Pfister SM et al. ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis. Acta Neuropathol 2013; 126(3): 443– 451. doi: 10.1007/ s00401‑ 013‑ 1156‑ z.

33. Reuss DE, Sahm F, Schrimpf D, Wiestler B, Capper D,Koelsche C et al. ATRX and IDH1– R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an „integrated“ diag-nostic approach for adult astrocytoma, oligodendroglioma and glioblastoma. Acta Neuropathol 2015: 129(1): 133– 146. doi: 10.1007/ s00401‑ 014‑ 1370‑ 3.

34. Haberler C, Wöhrer A. Clinical neuropathology practice news 2– 2014: ATRX, a new candidate biomarker in gliomas. Clin Neuropathol 2014; 33(2): 108– 111.

35. Panageas KS, Iwamoto FM, Cloughesy TF, Aldape KD,Rivera AL, Eichler AF et al. Initial treatment patterns over time for anaplastic oligodendroglial tumors. Neuro Oncol 2012; 14(6): 761– 767. doi: 10.1093/ neuonc/ nos065.

36. Vyzula R et al. Kapitola 23: Zhoubný novotvar mozku (C71). In: 19. vydání Modré knihy onkologické společnosti. Masarykův onkologicky ústav, Brno 2014: 162– 164.

37. Iwadate Y, Matsutani T, Shinozaki N, Saeki N. Anaplastic oligodendroglial tumors harboring 1p/ 19q deletion can be successfully treated without radiotherapy. Anticancer Res 2011; 31(12): 4475– 4479.

38. Ramirez C, Bowman C, Maurage CA, Dubois F, Blond S,Porchet N et al. Loss of 1p, 19q, and 10q heterozygosity prospectively predicts prognosis of oligodendroglial tumors – towards individualized tumor treatment? Neuro Oncol 2010; 12(5): 490– 499. doi: 10.1093/ neuonc/ nop071.

39. Polívka J, Polívka J jr, Rohan V, Přibáň V. Anaplastické oligodendrogliomy – nadešel čas pro personalizovanou medicínu? Cesk Slov Neurol N 2014; 77/ 110(4): 428– 434.

40. Gravendeel LA, Kouwenhoven MC, Gevaert O, de Rooi JJ, Stubbs AP, Duijm JE et al. Intrinsic gene expression profiles of gliomas are a better predictor of survival than histology. Cancer Res 2009; 69(23): 9065– 9072. doi: 10.1158/ 0008‑ 5472.CAN‑ 09‑ 2307.

41. Erdem‑ Eraslan L, Gravendeel LA, de Rooi J, Eilers PH, Idbaih A, Spliet WG et al. Intrinsic molecular subtypes of gliomaare prognostic and predict benefit from adjuvant procarbazine, lomustine, and vincristine chemotherapy in combination with other prognostic factors in anaplastic oligodendroglial brain tumors: a report from EORTC study 26951. J Clin Oncol 2013; 31(3): 328– 336. doi: 10.1200/ JCO.2012.44.1444.

42. Xie Q, Mittal S, Berens ME. Targeting adaptive glioblastoma: an overview of proliferation and invasion. Neuro Oncol 2014; 16(12): 1575– 1584. doi: 10.1093/ neuonc/ nou147.

43. Fadrus P, Lakomý R, Hübnerová P, Slabý O, Keřkovský M,Svoboda T et al. Interní Med 2010; 12(7– 8): 376– 381.